ArticleFrontiers in endocrinology2024
Ultrasonographic predictors of thyroid cancer in Bethesda III and IV thyroid nodules.
Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 9 citations in OpenAlex.
- Integrated Ultrasound Features, Cytologic Subclassification, and Systemic Inflammatory Markers for Predicting Malignancy in Bethesda III Thyroid Nodules.Journal of clinical medicine · 2026Article
- The Value of Multimodal Ultrasound in Differentiating Benign from Malignant Cytologically Indeterminate Thyroid Nodules.Cancers · 2026Article
- Integrating Ultrasound and Clinicopathologic Characteristics to Predict the Invasive Papillary Thyroid Carcinoma Among Indeterminate Thyroid Nodules.Cancer management and research · 2026Article
- A novel marker for predicting malignancy in patients with thyroid nodules diagnosed as AUS on initial cytology: thyroid hormone sensitivity.Frontiers in endocrinology · 2026Article
- Prevalence and predictors of malignancy in Bethesda III and IV thyroid nodules undergoing surgery.Frontiers in endocrinology · 2026Article
- Clinical Outcomes of Patients With Bethesda III or IV Cytology on Fine Needle Aspiration of Thyroid Nodules-A Retrospective Study.Endocrinology, diabetes & metabolism · 2025Article
- Ultrasound radiomics and genomics improve the diagnosis of cytologically indeterminate thyroid nodules.Frontiers in endocrinology · 2025Review
- Ultrasound radiomics models improve preoperative diagnosis and reduce unnecessary biopsies in indeterminate thyroid nodules.Frontiers in endocrinology · 2025Article
- Prediction of malignancy risk in Bethesda III nodules: development and validation of multiple machine learning models.Frontiers in endocrinology · 2025Article
- Rates and Predictors of Malignancy in Bethesda III and IV Thyroid Nodules: A Prospective Study.Cureus · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bethesda III and IV thyroid nodules continue to be difficult to manage. Although molecular testing may assist in decision-making, it is expensive, not widely available, and not without pitfalls. The objective of this study is to assess whether certain thyroid ultrasonographic features may predict the risk of thyroid cancer in patients with Bethesda III and IV thyroid nodules and be used as additional decision-making tools to complement cytopathological results in deciding on diagnostic thyroidectomy. Methods: We retrospectively evaluated the ultrasonographic features of Bethesda categories III and IV thyroid nodules in patients who underwent subsequent thyroidectomy. We used the final histopathological examination of the surgical specimens as the gold-standard test and analyzed individual preoperative ultrasonographic features as predictors of malignancy. Results: Of the 278 patients who were diagnosed with Bethesda III and IV thyroid nodules on fine needle aspiration cytology (FNAC), 111 (39.9%) had thyroid cancer, and 167 (59.9%) exhibited benign nodules. The malignancy rate was higher in patients with Bethesda IV nodules (28/50, 56%) than those with Bethesda III nodules (83/228, 36.4%; Conclusions: Hypoechogenicity and calcifications in Bethesda III and IV thyroid nodules are strong predictors of thyroid cancer and associated with a two-fold increased risk of malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.